omeprazole has been researched along with Ciliary Motility Disorders in 1 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Ciliary Motility Disorders: Conditions caused by abnormal CILIA movement in the body, usually causing KARTAGENER SYNDROME, chronic respiratory disorders, chronic SINUSITIS, and chronic OTITIS. Abnormal ciliary beating is likely due to defects in any of the 200 plus ciliary proteins, such as missing motor enzyme DYNEIN arms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The ulcers scarred after the long-term administration of a proton pump inhibitor (PPI), but recurred after the suspension." | 1.35 | Recurrent peptic ulcer disease in a pediatric patient with type 1 neurofibromatosis and primary ciliary dyskinesia. ( Di Stefano, V; Francavilla, R; Lionetti, E; Pavone, L; Principi, MB; Ruggieri, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lionetti, E | 1 |
| Francavilla, R | 1 |
| Ruggieri, M | 1 |
| Di Stefano, V | 1 |
| Principi, MB | 1 |
| Pavone, L | 1 |
1 other study available for omeprazole and Ciliary Motility Disorders
| Article | Year |
|---|---|
Recurrent peptic ulcer disease in a pediatric patient with type 1 neurofibromatosis and primary ciliary dyskinesia.
Topics: Adult; Age Factors; Anti-Ulcer Agents; Child, Preschool; Ciliary Motility Disorders; Female; Follow- | 2009 |